Palifermin for management of treatment-induced oral mucositis in cancer patients.
about
Topical KGF treatment as a therapeutic strategy for vaginal atrophy in a model of ovariectomized mice.Keratinocyte growth factor administration attenuates murine pulmonary mycobacterium tuberculosis infection through granulocyte-macrophage colony-stimulating factor (GM-CSF)-dependent macrophage activation and phagolysosome fusionFactors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinomaEmerging new clinical applications for palifermin: beyond its use in oral mucositis and graft versus host disease.Craniomaxillofacial Disorders and Solutions in Humans and Animals.
P2860
Palifermin for management of treatment-induced oral mucositis in cancer patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@en
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@nl
type
label
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@en
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@nl
prefLabel
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@en
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@nl
P2093
P2860
P356
P1476
Palifermin for management of treatment-induced oral mucositis in cancer patients.
@en
P2093
Andrei Barasch
Joel Epstein
Ken Tilashalski
P2860
P304
P356
10.2147/BTT.2009.2871
P577
2009-07-13T00:00:00Z